Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Thomas Mathias Gress

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9333-5461; OpenAlex author ID A5080497221, A5142767908, A5158542081. Sources: OpenAlex.

Their work

Papers
72 (first author 7, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
239
Papers, trials and grants by year

2011: 3 papers · 2012: 5 papers · 2013: 10 papers · 2014: 3 papers · 2015: 5 papers · 2016: 6 papers · 2017: 4 papers · 2018: 3 papers · 2019: 3 papers · 2020: 6 papers · 2021: 7 papers · 2022: 1 paper · 2023: 5 papers · 2024: 4 papers · 2025: 4 papers · 2026: 3 papers

Papers 50 of 72

  1. Emerging concepts, hot topics, and open questions in today's pancreatic cancer research. Co-author DOI 10.1016/j.bbcan.2026.189614↗
  2. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  3. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  4. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Co-author DOI 10.1002/ijc.35397↗
  5. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Last author DOI 10.1002/ueg2.12676↗
  6. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  7. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  8. Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant-negative familial pancreatic … Co-author DOI 10.1002/ueg2.12631↗
  9. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  10. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331854↗
  11. Optimized Spheroid Model of Pancreatic Cancer Demonstrates Influence of Macrophage-T Cell Interaction for Intratumoral T Cell Motility. Co-author DOI 10.3390/cancers17010051↗
  12. Dissecting the role of toll-like receptor 7 in pancreatic cancer. Co-author DOI 10.1002/cam4.5606↗
  13. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Co-author DOI 10.1136/gutjnl-2022-327855↗
  14. IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model. Co-author DOI 10.1158/2326-6066.cir-22-0398↗
  15. Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. Co-author DOI 10.3389/fcell.2023.1179559↗
  16. IL18 Receptor Signaling Inhibits Intratumoral CD8+ T-Cell Migration in a Murine Pancreatic Cancer Model. Co-author DOI 10.3390/cells12030456↗
  17. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  18. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  19. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  20. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  21. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  22. The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)—Knowledge Gained in 20 Years. Co-author DOI 10.3238/arztebl.m2021.0004↗
  23. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.743908↗
  24. Unraveling the Molecular Tumor-Promoting Regulation of Cofilin-1 in Pancreatic Cancer. Co-author DOI 10.3390/cancers13040725↗
  25. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  26. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  27. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  28. Microenvironmental Determinants of Pancreatic Cancer. Co-author DOI 10.1152/physrev.00042.2019↗
  29. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  30. The Immune Microenvironment in Pancreatic Cancer. Co-author DOI 10.3390/ijms21197307↗
  31. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  32. Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-019-11752-2↗
  33. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Last author DOI 10.1136/gutjnl-2018-316451↗
  34. [Pancreatic ductal adenocarcinoma]. First author DOI 10.1007/s00108-018-0460-z↗
  35. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-018-03962-x↗
  36. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Co-author DOI 10.1093/ije/dyx269↗
  37. A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Co-author DOI 10.1093/annonc/mdx167↗
  38. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-310049↗
  39. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Co-author DOI 10.1136/gutjnl-2015-310442↗
  40. The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators. Co-author DOI 10.18632/oncotarget.19882↗
  41. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.02.057↗
  42. miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer. Co-author DOI 10.1080/2162402x.2016.1160181↗
  43. Refinement of screening for familial pancreatic cancer. Last author DOI 10.1136/gutjnl-2015-311098↗
  44. PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulator… Co-author DOI 10.1158/0008-5472.can-15-0216↗
  45. GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/1535-7163.mct-15-0309↗
  46. DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-016-2052-4↗
  47. Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. Co-author DOI 10.1016/j.jss.2015.03.070↗
  48. Controversy on the time to progression of pancreatic ductal adenocarcinoma. Last author DOI 10.1136/gutjnl-2014-309066↗
  49. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Last author DOI 10.1136/gutjnl-2015-309304↗
  50. Emerging role of microRNAs to tackle drug resistance in pancreatic cancer. First author DOI 10.1136/gutjnl-2015-309503↗

Closest collaborators

The 25 strongest of 239 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Malte Buchholz · 22 shared papers, 2011–2025 · strength 2.09
  2. Magdalena Huber · 9 shared papers, 2016–2026 · strength 1.39
  3. Alfredo Carrato · 14 shared papers, 2016–2025 · strength 1.28
  4. Detlef Klaus Bartsch · 14 shared papers, 2012–2024 · strength 1.28
  5. Christian Alexander Bauer · 8 shared papers, 2016–2024 · strength 1.10
  6. Rita Teresa Lawlor · 9 shared papers, 2017–2025 · strength 0.99
  7. Aldo Scarpa · 11 shared papers, 2014–2025 · strength 0.99
  8. Núria Malats · 10 shared papers, 2017–2025 · strength 0.97
  9. Jorg H. Kleeff · 11 shared papers, 2015–2025 · strength 0.89
  10. William Greenhalf · 10 shared papers, 2017–2025 · strength 0.84
  11. Patrick Michl · 15 shared papers, 2011–2021 · strength 0.80
  12. Francisco X. Real · 10 shared papers, 2014–2025 · strength 0.79
  13. Matthias Lauth · 5 shared papers, 2019–2026 · strength 0.79
  14. Luis Muñoz‐Bellvís · 9 shared papers, 2017–2025 · strength 0.76
  15. J. Enrique Domínguez‐Muñoz · 9 shared papers, 2017–2025 · strength 0.76
  16. Tatjana Crnogorac‐Jurcevic · 9 shared papers, 2017–2025 · strength 0.76
  17. Corinna Ulrike Keber · 4 shared papers, 2023–2026 · strength 0.76
  18. Emily P. Slater · 8 shared papers, 2013–2024 · strength 0.75
  19. Veronika Lutz · 4 shared papers, 2023–2024 · strength 0.65
  20. Albrecht Neeße · 10 shared papers, 2011–2020 · strength 0.64
  21. Eithne Costello · 9 shared papers, 2016–2024 · strength 0.63
  22. Matthias J. Löhr · 8 shared papers, 2017–2025 · strength 0.62
  23. Christoph W. Michalski · 8 shared papers, 2015–2024 · strength 0.59
  24. Linda Sharp · 8 shared papers, 2017–2024 · strength 0.58
  25. Bo Kong · 8 shared papers, 2017–2024 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.